Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,411,785
  • Shares Outstanding, K 57,343
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,530 K
  • EBIT $ -183 M
  • EBITDA $ -200 M
  • 60-Month Beta -1.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 67.82% ( -14.47%)
  • Historical Volatility 97.63%
  • IV Percentile 5%
  • IV Rank 5.78%
  • IV High 224.41% on 05/31/24
  • IV Low 58.22% on 08/23/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 434
  • Volume Avg (30-Day) 560
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 15,950
  • Open Int (30-Day) 15,344

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.26
  • Number of Estimates 8
  • High Estimate -0.17
  • Low Estimate -0.32
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.80 +46.69%
on 04/14/25
28.68 -14.07%
on 05/02/25
+8.74 (+55.00%)
since 04/11/25
3-Month
13.22 +86.42%
on 04/09/25
28.68 -14.07%
on 05/02/25
+0.27 (+1.13%)
since 02/13/25
52-Week
13.22 +86.42%
on 04/09/25
62.74 -60.72%
on 06/03/24
-11.35 (-31.52%)
since 05/13/24

Most Recent Stories

More News
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

GPCR : 24.67 (+0.20%)
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

VKTX : 27.36 (-3.32%)
GPCR : 24.67 (+0.20%)
PFE : 22.69 (-1.73%)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

VKTX : 27.36 (-3.32%)
NVO : 65.75 (-2.94%)
LLY : 755.97 (+0.05%)
GPCR : 24.67 (+0.20%)
PFE : 22.69 (-1.73%)
The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:

GIS : 53.64 (-2.19%)
VKTX : 27.36 (-3.32%)
NVO : 65.75 (-2.94%)
HIMS : 60.72 (+9.98%)
LLY : 755.97 (+0.05%)
CAG : 22.80 (-2.19%)
GPCR : 24.67 (+0.20%)
ISRG : 567.03 (+1.00%)
PFE : 22.69 (-1.73%)
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

GPCR : 24.67 (+0.20%)
Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim...

LLY : 755.97 (+0.05%)
GPCR : 24.67 (+0.20%)
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

GPCR : 24.67 (+0.20%)
AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

LLY : 755.97 (+0.05%)
GPCR : 24.67 (+0.20%)
SDGR : 23.91 (-1.08%)
NVS : 107.64 (-1.20%)
RXRX : 4.56 (-1.72%)
Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

ACCG-2671 shows promise for weight loss and safety, with Phase 1 trials planned by late 2025.Quiver AI SummaryStructure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin...

GPCR : 24.67 (+0.20%)
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

GPCR : 24.67 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 28.85
2nd Resistance Point 27.88
1st Resistance Point 26.25
Last Price 24.67
1st Support Level 23.64
2nd Support Level 22.67
3rd Support Level 21.04

See More

52-Week High 62.74
Fibonacci 61.8% 43.82
Fibonacci 50% 37.98
Fibonacci 38.2% 32.14
Last Price 24.67
52-Week Low 13.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar